This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.
Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care.
10 years of age or older
Documented, signed, dated informed consent to participate in the microdevice study
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
None
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator